Clinical Trials · NCT03336983
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- Enrollment
- 126
- Start date
- Dec 2017
- Locations
- 1 site, Italy
- Primary endpoint
- Evaluation of change in bone response after 6 and 12 months of treatment compared to baseline